Cipla Ltd. Joins Challengers To Sanofi-Synthelabo’s Plavix Drug

October 19, 2005 |

1 min read

Cipla and its partner Watson Pharmaceuticals plan to seek US approval for a generic version of Sanofi-Synthelabo's blood-thinning drug Plavix, Cipla's chairman said on Monday.

Alliances FDA Approvals Regulatory

MORE ON THIS TOPIC

Winding road leads to the light of the lighthouse. Stock vector illustration

Rare diseases

Oak Hill takes SPAC track to Nasdaq with Roche asset in tow

July 28, 2026

·

2 min read

·

Tristan Manalac

Laptop with envelope and document with exclamation mark on screen. Receive notification, alert message, warning, get e-mail, email, spam concepts. Flat design vector illustration

FDA

UPDATE: FDA disputes Capricor’s claims of Phase 3 success for DMD cell therapy

July 27, 2026

·

3 min read

·

Heather McKenzie

3D Paper Cut Pair of Lung dotted with yellow tumor bacteria infection spread across on a blue background with no text. Yellow dots as virus infection in the lungs. Vector Illustration.

Business

Gossamer regains rights to lung disease asset from Chiesi after Phase 3 fail

July 27, 2026

·

3 min read

·

Gabrielle Masson

Easy Way or Shortcut to Business Success. Businessman on the Straight and Complicated Path. vector

C-suite

Sarepta names former AbbVie R&D exec Michael Severino as next CEO

July 27, 2026

·

3 min read

·

Annalee Armstrong